10.1 503A Compounding Pharmacies

Compounding is the preparation, mixing, assembling, packaging, or labeling of a drug to fit a patient's specific need. The legal framework that governs traditional compounding pharmacies is Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA), which was clarified and amended by the Drug Quality and Security Act (DQSA) of 2013. For the PTCB Supply Chain exam, you must know what a 503A pharmacy is, who regulates it, what standards it follows, and how it sits inside (and partly outside) the DSCSA traceability framework.

What Section 503A Establishes

A 503A compounding pharmacy is a traditional compounding pharmacy that compounds drugs pursuant to a patient-specific prescription from an authorized prescriber. The defining feature is the patient-specific Rx: the compound is made for an identified individual patient, dispensed against that prescription, and is not produced as a batch for general office use. Limited quantities of anticipation compounding are allowed based on a documented history of prescriptions, but the core model is Rx-driven, one-patient-at-a-time compounding.

Key 503A rules:

• Compounds per a patient-specific prescription (or, in limited anticipation, based on a documented history of prescriptions)
• Is not required to register with FDA as an outsourcing facility
• Is not subject to current Good Manufacturing Practice (cGMP) as a facility
• May not compound drugs that have been withdrawn from the market for safety or efficacy reasons, and may not compound what is essentially a copy of a commercially available product

State Board Regulation — Not FDA

This is one of the most-tested contrasts on the exam. A 503A pharmacy is regulated primarily by the state board of pharmacy, not by the FDA as a facility. The state board licenses the pharmacy, inspects it, sets permissible compounding scope, and enforces standards. FDA's role is narrower — it may act against adulteration or misbranding — but the day-to-day facility regulator is the state. By contrast, a 503B outsourcing facility registers with and is inspected by FDA (covered in section 10.2).

USP <795> and USP <797> Standards

503A pharmacies must follow the USP compounding chapters:

• USP <795> — Pharmaceutical Compounding—Nonsterile Preparations. Covers nonsterile compounds (creams, oral suspensions, capsules, troches). Defines ingredients, beyond-use dating, environment, and documentation.
• USP <797> — Pharmaceutical Compounding—Sterile Preparations. Covers sterile compounds (IVs, ophthalmics, injectables). Defines ISO-classified spaces, garbing, aseptic technique, and beyond-use dating by risk level.

A pharmacy doing both sterile and nonsterile compounding must satisfy both chapters. Hazardous drug compounding additionally follows USP <800>, which ties back to the Laws/Regulations domain.

DSCSA: Compounded Drugs Are Excluded

Under the Drug Supply Chain Security Act (DSCSA), a compounded human drug product compounded under Section 503A is excluded from DSCSA serialization and track-and-trace requirements. DSCSA was built for manufactured, packaged products moving through wholesale trading partners — not for a tailor-made compound dispensed to one patient. So a 503A pharmacy is generally outside DSCSA serialization for its compounded output.

However, 503A pharmacies still operate inside the broader supply chain when they source ingredients. Active pharmaceutical ingredients (APIs), excipients, and bulk drug substances must be obtained from registered, reputable suppliers. FDA publishes a list of bulk substances that may be used in 503A compounding (the 503A bulks list). Ingredients are typically USP or NF grade, and records of ingredient lot, supplier, and certificate of analysis must be retained per state board rules.

503A vs 503B — The Anchor Contrast

The exam repeatedly tests the 503A-vs-503B distinction. At a glance:

Both 503A and 503B compounded drugs are excluded from DSCSA track-and-trace; the difference is that 503B is still an FDA-registered facility and is a defined "trading partner" type for other DSCSA purposes.

In Practice

A community pharmacy that compounds a child's amoxicillin oral suspension from a powder because the commercially available concentration does not match the prescribed dose is operating under 503A: patient-specific Rx, state-board regulated, USP <795> nonsterile standards, no FDA registration, and the compounded suspension is not serialized under DSCSA. The pharmacy must still retain the compounding record, ingredient lot, and Rx per state board rules.

Worked Example — Why the Regulator Matters

Imagine two pharmacies each compound a sterile eye drop. Pharmacy A is a 503A community pharmacy filling one patient's Rx; its sterile work is judged against USP <797>, and a state board inspector reviews it. Pharmacy B is a 503B outsourcing facility making the same drop in 5,000-unit batches for hospital stock; its work is judged against cGMP, and an FDA inspector reviews it. Same drug, very different regulator and very different standard — and that is exactly the axis the exam tests.